NCT07122713 Definitive Radiation Therapy for Inoperable Breast Cancer
| NCT ID | NCT07122713 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Alexander Stessin |
| Condition | Breast Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-12-08 |
| Primary Completion | 2028-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2025-12-08 with a primary completion date of 2028-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to find out if adding radiation therapy to routine medications for breast cancer helps in reducing and preventing the cancer from getting worse. Patients with a locally advanced breast cancer who cannot, or do not want to, undergo surgery are eligible to participate. Participation in this study does not prevent you from undergoing surgery in the future.
Eligibility Criteria
Inclusion Criteria: * Biopsy proven invasive carcinoma of the breast, either lobular, ductal and/or no special type * T1-T4, N0-2, M0-1 invasive breast carcinoma by radiological or clinical criteria * Cancer is deemed unresectable, or the patient is a poor surgical candidate as determined following evaluation by a surgeon, or patient declines surgery. * Life expectancy \> 6 months * Negative pregnancy test at the time of start of treatment in any female of reproductive age Exclusion Criteria: * Concurrent systemic therapy (except for endocrine therapy, HER2-targeted therapy, or immunotherapy which are permitted) * Prior radiation to ipsilateral breast or regional nodes * Inability to receive study treatment planning and treatment secondary to body habitus
Contact & Investigator
Caterina Stony Brook Cancer Center Clinical Trials
✉ cancerclinicaltrials@sronybrookmedicine.edu📞 631-728-7425
Alexander Stessin, MD PhD
PRINCIPAL INVESTIGATOR
Stony Brook University Hospital
Frequently Asked Questions
Who can join the NCT07122713 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07122713 currently recruiting?
Yes, NCT07122713 is actively recruiting participants. Contact the research team at cancerclinicaltrials@sronybrookmedicine.edu for enrollment information.
Where is the NCT07122713 trial being conducted?
This trial is being conducted at Stony Brook, United States.
Who is sponsoring the NCT07122713 clinical trial?
NCT07122713 is sponsored by Alexander Stessin. The principal investigator is Alexander Stessin, MD PhD at Stony Brook University Hospital. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.